mNOX-E36-3’PEG, an MCP-1 antagonist, can reduce macrophage recruitment to the glomerulus and renal interstitium of diabetic mice by targeting the MCP-1/CCR2 axis and alleviating renal fibrosis in mice with experimental DN.[63]. This evidence concerns the gene CCR2 and liver dysplastic nodule.